Literature DB >> 28571241

Acute Respiratory Distress Syndrome Complicated by Amiodarone Induced Pulmonary Fibrosis: Don't Let Your Guard Down.

Vipin Kumar Singh1, Vijeta Maheshwari2.   

Abstract

Amiodarone is an antiarrhythmic agent which is commonly used to treat both supraventricular and ventricular arrhythmias. This iodine containing compound has been associated with several adverse events like it tends to accumulate in several organs. Among those, the most serious is Amiodarone Pulmonary Toxicity (APT). While the incidence of this complication has decreased with the use of lower doses of amiodarone but it can occur with any dose. Pulmonary complications usually present as an acute or subacute pneumonitis. On chest X-ray and high-resolution Computed Tomography (CT), diffuse infiltrates were found. Here, we present a case in which acute respiratory distress syndrome like features were detected which got subsided after stopping tablet amiodarone. The patient was a known case of atrial fibrillation for which she was taking tablet amiodarone for the last six months.

Entities:  

Keywords:  Arrhythmia; Pulmonary toxicity; Upper respiratory tract infection

Year:  2017        PMID: 28571241      PMCID: PMC5449887          DOI: 10.7860/JCDR/2017/24710.9674

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

Review 1.  Amiodarone for atrial fibrillation.

Authors:  Peter Zimetbaum
Journal:  N Engl J Med       Date:  2007-03-01       Impact factor: 91.245

2.  Amiodarone pulmonary toxicity.

Authors:  G A Jessurun; H J Crijns
Journal:  BMJ       Date:  1997-03-01

Review 3.  Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?

Authors:  Martin Schwaiblmair; Thomas Berghaus; Thomas Haeckel; Theodor Wagner; Wolfgang von Scheidt
Journal:  Clin Res Cardiol       Date:  2010-07-10       Impact factor: 5.460

4.  Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse.

Authors:  Kaori Okayasu; Yuichiro Takeda; Jun Kojima; Atsuto Yoshizawa; Nobuyuki Kobayashi; Haruhito Sugiyama; Koichiro Kudo
Journal:  Intern Med       Date:  2006-12-15       Impact factor: 1.271

Review 5.  Prescribing amiodarone: an evidence-based review of clinical indications.

Authors:  Patricia Vassallo; Richard G Trohman
Journal:  JAMA       Date:  2007-09-19       Impact factor: 56.272

6.  Pulmonary toxicity in patients receiving low-dose amiodarone.

Authors:  Michael C Ott; Andras Khoor; Jack P Leventhal; Timothy E Paterick; Charles D Burger
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

7.  Amiodarone-induced pulmonary toxicity mimicking acute pulmonary edema.

Authors:  Iacopo Fabiani; Danilo Tacconi; Simone Grotti; Rossella Brandini; Claudia Salvadori; Marcello Caremani; Leonardo Bolognese
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2011-05       Impact factor: 2.160

8.  Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone.

Authors:  Yuichiro Yamada; Tsuyoshi Shiga; Naoki Matsuda; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Circ J       Date:  2007-10       Impact factor: 2.993

9.  Amiodarone-induced pulmonary toxicity.

Authors:  Desak Ketut Ernawati; Leanne Stafford; Jeffery David Hughes
Journal:  Br J Clin Pharmacol       Date:  2008-05-06       Impact factor: 4.335

  9 in total
  2 in total

1.  Altered Mental Status and Hyponatremia After 20 Hours of Amiodarone Therapy.

Authors:  Andrea Qi; John C Moscona; Justin Reed; Thierry H Le Jemtel
Journal:  Tex Heart Inst J       Date:  2020-06-01

2.  Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study.

Authors:  Martin Balik; Petr Waldauf; Michal Maly; Vojtech Matousek; Tomas Brozek; Jan Rulisek; Michal Porizka; Robert Sachl; Michal Otahal; Petr Brestovansky; Eva Svobodova; Marek Flaksa; Zdenek Stach; Jaroslav Pazout; Frantisek Duska; Ondrej Smid; Martin Stritesky
Journal:  BMJ Open       Date:  2019-09-03       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.